Sie befinden sich hier
Inhalt
Heart failure (HF) is a leading cause of morbidity and mortality worldwide, with its prevalence continuing to increase. Hallmarks of HF include enhanced activity of the sympathetic nervous system and the renin–angiotensin–aldosterone system (RAAS), which contribute to maladaptive remodeling processes such as cardiac hypertrophy and fibrosis. Accordingly, inhibition of maladaptive neurohumoral signaling remains a cornerstone of current heart failure therapy. Despite substantial advances in treatment, HF remains associated with a poor prognosis. A better understanding of the molecular and cellular remodeling processes that precede overt HF is therefore essential for the development of novel therapeutic strategies.
Our research focuses on the molecular signaling mechanisms that drive cardiac remodeling and contribute to the development and progression of heart failure. We are particularly interested in how intracellular signaling networks and intercellular communication between different cardiac cell types regulate cardiomyocyte function, hypertrophy, and fibrosis.
Many neurohumoral systems exert their effects on cardiac cells by activating G protein-coupled receptors (GPCRs). We investigate how GPCR-dependent signaling control second messengers, protein phosphorylation, and calcium handling, how these pathways are altered during chronic cardiac stress, and how their pharmacological modulation may preserve or restore cardiac function.
In parallel, we study heterocellular signaling within the heart. Cardiomyocytes, cardiac fibroblasts, and other cardiac cell types form a highly interconnected signaling network, and maladaptive communication between these cells can critically contribute to pathological remodeling. We aim to identify signaling pathways and paracrine factors that initiate or propagate these processes and to define their cellular sources and targets.
Our overall goal is to understand how cardiac signaling networks are remodeled during disease and to identify mechanisms that can be exploited for novel therapeutic approaches in heart failure.
To address these questions, we combine pharmacological and genetic approaches in primary cardiac cells and human stem cell-derived cardiomyocytes with biochemical and molecular analyses. These studies are complemented by omics approaches and in vivo models of cardiac stress, remodeling, and heart failure.
Selected Publications
- Wibowo YC, Ma N, Ren, Y, Cordero J, Gahn J, Chen Z, Lévay M, Ola R, Feng Y, Dobreva G, Wieland T, Vettel C & Jansen S. Endothelial Epac1 facilitates YAP/TAZ controlled melanoma growth and angiogenesis. Angiogenesis 29, 72 (2026). https://doi.org/10.1007/s10456-026-10080-6
- Shao F, Wieland J, Wang Y, Keles M, Meng Z, Lomada S, Qin M, Leiss V., Martin-Garrido A, Fuhrmann M, Qiu Y, Trogisch FA, Vettel C, Heineke J, Feng Y. Deficiency in nucleoside diphosphate kinase B leads to endothelial activation of the hexosamine biosynthesis pathway and cardiac dysfunction. Cardiovasc Diabetol 2025 24, 84
- Cachorro E, Günscht M, Schubert M, Sadek MS, Siegert J, Dutt F, Bauermeister C, Quickert S, Berning H, Nowakowski F, Lämmle S, Firneburg R, Luo X, Künzel SR, Klapproth E, Mirtschink P, Mayr M, Dewenter M, Vettel C, Heijman J, Lorenz K, Guan K, El-Armouche A, Wagner M, Kämmerer S. CNP Promotes Antiarrhythmic Effects via Phosphodiesterase 2. Circ Res. 2023 Feb 17;132(4):400-414.
- Dewenter M, Pan J, Knödler L, Tzschöckel N, Henrich J, Cordero J, Dobreva G, Lutz S, Backs J, Wieland T & Vettel C. Chronic isoprenaline/phenylephrine vs. exclusive isoprenaline stimulation in mice: critical contribution of alpha1-adrenoceptors to early cardiac stress responses. Basic Res Cardiol. 2022 Mar 14;117(1):15.
- Tóth AD, Schell R, Lévay M, Vettel C, Theis P, Haslinger C, Alban F, Werhahn S, Frischbier L, Krebs-Haupenthal J, Thomas D, Gröne HJ, Avkiran M, Katus HA, Wieland T, Backs J. Inflammation leads through PGE/EP3 signaling to HDAC5/MEF2-dependent transcription in cardiac myocytes. EMBO Mol Med. 2018 Jul;10(7):e8536.
- Abu-Taha IH, Heijman J, Hippe HJ, Wolf NM, El-Armouche A, Nikolaev VO, Schäfer M, Würtz CM, Neef S, Voigt N, Baczkó I, Varró A, Müller M, Meder B, Katus HA, Spiger K, Vettel C, Lehmann LH, Backs J, Skolnik EY, Lutz S, Dobrev D, Wieland T. Nucleoside Diphosphate Kinase-C Suppresses cAMP Formation in Human Heart Failure. Circulation. 2017 Feb 28;135(9):881-897.
- Vettel C, Lindner M, Dewenter M, Lorenz K, Schanbacher C, Riedel M, Lämmle S, Meinecke S, Mason FE, Sossalla S, Geerts A, Hoffmann M, Wunder F, Brunner FJ, Wieland T, Mehel H, Karam S, Lechêne P, Leroy J, Vandecasteele G, Wagner M, Fischmeister R, El-Armouche A. Phosphodiesterase 2 Protects Against Catecholamine-Induced Arrhythmia and Preserves Contractile Function After Myocardial Infarction. Circ Res. 2017 Jan 6;120(1):120-132.
- Vettel C, Lämmle S, Ewens S, Cervirgen C, Emons J, Ongherth A, Dewenter M, Lindner D, Westermann D, Nikolaev VO, Lutz S, Zimmermann WH, El-Armouche A. PDE2-mediated cAMP hydrolysis accelerates cardiac fibroblast to myofibroblast conversion and is antagonized by exogenous activation of cGMP signaling pathways. Am J Physiol Heart Circ Physiol. 2014 Apr 15;306(8):H1246-52.
- Vettel C, Hottenrott MC, Spindler R, Benck U, Schnuelle P, Tsagogiorgas C, Krämer BK, Hoeger S, El-Armouche A, Wieland T, Yard BA. Dopamine and lipophilic derivates protect cardiomyocytes against cold preservation injury. J Pharmacol Exp Ther. 2014 Jan;348(1):77-85.
- Vettel C, Wittig K, Vogt A, Wuertz CM, El-Armouche A, Lutz S, Wieland T. A novel player in cellular hypertrophy: Giβγ/PI3K-dependent activation of the RacGEF TIAM-1 is required for α₁-adrenoceptor induced hypertrophy in neonatal rat cardiomyocytes. J Mol Cell Cardiol. 2012 Aug;53(2):165-75.
Kontextspalte
Group Leader
Dr. Christiane Vettel
Phone +49 621 383-71754
christiane.vettel@medma.uni-heidelberg.de